|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Satsuma Pharmaceuticals, Inc. (STSA) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
31,530,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company developing a therapeutic product for the acute treatment of migraine. Co.'s product candidate, STS101, is a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is designed to be self-administered with a proprietary pre-filled, single-use, nasal delivery device. Co.'s development plan for STS101 included a completed Phase 1 trial; a Phase 3 efficacy trial (the SUMMIT trial), which is ongoing; and continuation of the open-label, Phase 3 long-term safety trial of STS101 (the ASCEND trial).
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
52,530,894 |
59,120,894 |
Total Buy Value |
$0 |
$0 |
$47,803,114 |
$52,304,126 |
Total People Bought |
0 |
0 |
2 |
3 |
Total Buy Transactions |
0 |
0 |
3 |
6 |
Total Shares Sold |
0 |
0 |
0 |
3,250,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$2,294,500 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kolchinsky Peter |
Former 10% Owner |
|
2023-06-08 |
4 |
D |
$0.00 |
$0 |
I/I |
(5,914,252) |
0 |
|
- |
|
Shin Nippon Biomedical Laboratories, Ltd. |
10% Owner |
|
2023-06-08 |
4 |
B |
$0.91 |
$7,665,596 |
I/I |
8,423,732 |
8,423,732 |
1.5 |
- |
|
Shin Nippon Biomedical Laboratories, Ltd. |
10% Owner |
|
2023-06-06 |
4 |
B |
$0.91 |
$20,068,759 |
I/I |
22,053,581 |
22,053,581 |
1.5 |
- |
|
Takanashi Ken |
Director |
|
2023-06-06 |
4 |
B |
$0.91 |
$20,068,759 |
I/I |
22,053,581 |
24,847,694 |
2.25 |
- |
|
Oneil Thomas P. |
Chief Financial Officer |
|
2023-06-06 |
4 |
D |
$0.91 |
$12,628 |
D/D |
(13,877) |
0 |
|
- |
|
Kollins John A |
President and CEO |
|
2023-06-06 |
4 |
D |
$0.91 |
$278,379 |
D/D |
(305,911) |
0 |
|
- |
|
Shah Rajeev M. |
Director |
|
2023-06-06 |
4 |
D |
$0.91 |
$5,381,969 |
I/I |
(5,914,252) |
0 |
|
- |
|
Leonard Braden Michael |
10% Owner |
|
2022-11-21 |
4 |
B |
$0.71 |
$106,740 |
D/D |
150,000 |
150,000 |
2.45 |
- |
|
Leonard Braden Michael |
10% Owner |
|
2022-11-15 |
4 |
B |
$0.63 |
$525,663 |
I/I |
831,694 |
6,440,000 |
1.5 |
- |
|
Leonard Braden Michael |
10% Owner |
|
2022-11-14 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,608,306 |
|
- |
|
Commodore Capital Lp |
10% Owner |
|
2022-11-14 |
4 |
S |
$0.71 |
$2,294,500 |
I/I |
(3,250,000) |
461,286 |
|
- |
|
Leonard Braden Michael |
10% Owner |
|
2022-11-14 |
4 |
B |
$0.69 |
$3,868,609 |
I/I |
5,608,306 |
5,608,306 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-11-24 |
4 |
B |
$5.42 |
$15,837 |
I/I |
2,922 |
3,711,286 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-11-11 |
4 |
B |
$6.05 |
$48,043 |
I/I |
7,941 |
3,695,160 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-11-10 |
4 |
B |
$5.85 |
$56,289 |
I/I |
9,622 |
3,687,219 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-11-08 |
4 |
B |
$5.99 |
$3,354 |
I/I |
560 |
3,677,597 |
1.42 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-11-05 |
4 |
B |
$5.95 |
$46,410 |
I/I |
7,800 |
3,677,037 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-11-04 |
4 |
B |
$5.88 |
$8,232 |
I/I |
1,400 |
3,669,237 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-11-02 |
4 |
B |
$5.64 |
$50,083 |
I/I |
8,880 |
3,667,837 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-10-29 |
4 |
B |
$5.71 |
$254,957 |
I/I |
44,651 |
3,658,957 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-10-28 |
4 |
B |
$5.55 |
$83,705 |
I/I |
15,082 |
3,614,306 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-10-27 |
4 |
B |
$5.45 |
$215,716 |
I/I |
39,581 |
3,599,224 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-10-22 |
4 |
B |
$5.51 |
$152,236 |
I/I |
27,629 |
3,559,643 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-10-21 |
4 |
B |
$5.40 |
$177,206 |
I/I |
32,816 |
3,532,014 |
1.5 |
- |
|
Commodore Capital Lp |
10% Owner |
|
2021-10-20 |
4 |
B |
$5.44 |
$221,207 |
I/I |
40,663 |
3,499,198 |
1.5 |
- |
|
74 Records found
|
|
Page 1 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|